Pamela Gustafson

    Pamela Gustafson
    Vice President, Clinical Research
    Pamela Gustafson joined Proteon in 2006 and has served as our Vice President, Clinical Research since 2015, prior to which she was the Senior Director of Clinical Research from 2012 until 2014 and Director of Clinical Research from 2006 until 2012. Prior to joining Proteon, Ms. Gustafson served as Director of Clinical Operations at Trine Pharmaceuticals from 2002 to 2006. Prior to that, Ms. Gustafson worked as a Project Manager at AAI International from 1999 until 2002, LeukoSite, Inc. from 1998 until 1999, and PAREXEL International from 1996 until 1998. Prior to PAREXEL, Ms. Gustafson spent ten years, from 1986 to 1996, in drug development positions at Alkermes, Seragen, Genzyme Corporation, and the Massachusetts Eye and Ear Infirmary. Ms. Gustafson holds a B.A. from Wheaton College and an M.P.H. from Boston University. Ms. Gustafson is also certified as a Project Management Professional.

    Scott Toner

      Scott Toner
      Senior Vice President, Commercial
      Scott Toner joined Proteon in 2015 as our Senior Vice President, Marketing. Prior to joining Proteon, from 2014 to 2015, Mr. Toner served as the VP Marketing and Sales of OPKO Health’s Renal Division. From 2013 to 2014, he served as a consultant to companies in the biotechnology industry and from 2011 to 2012 served as Senior Director, Marketing of Reata Pharmaceuticals. Prior to that, from 2007 to 2010, Mr. Toner served as Executive Director of Marketing with AMAG Pharmaceuticals. From 1985 to 2007, Mr. Toner held various roles within the domestic and international divisions of Abbott Laboratories, concentrating primarily on the nephrology and critical care therapeutic spaces. Mr. Toner holds a B.A. from Ithaca College and an M.B.A. from Drexel University.

      F. Nicholas Franano, M.D.

        F. Nicholas Franano, M.D.
        Founder, Proteon Therapeutics, Inc.
        F. Nicholas Franano, M.D., has served as a member of our board of directors since 2006. Dr. Franano is currently President and Chief Executive Officer of Flow Forward Medical, Inc., and Metactive Medical, Inc., two companies developing cardiovascular medical devices, where he has served since 2014. Prior to this, Dr. Franano was founder, President and Chief Executive Officer of Novita Therapeutics, a medical device incubator company. Dr. Franano founded Proteon, and served as our Chief Executive Officer from 2001 to 2006, and after that as our Chief Scientific Officer from 2006 to 2009. Dr. Franano received an M.D. and an M.A. in biomedical research from Washington University, St. Louis, and a B.S. in cell biology from the University of Kansas. He completed a residency in diagnostic radiology and a fellowship in interventional radiology at the Johns Hopkins Hospital. Prior to founding Proteon, Dr. Franano maintained a clinical practice in interventional radiology from 2000 through 2005.

        Todd Foley

          Todd Foley
          Managing Director, MPM Capital
          Todd Foley has served as a member of our board of directors since 2012. Since 1999, Mr. Foley has been a managing director with MPM Capital, a venture capital firm, working from its Boston office. Prior to joining MPM, Mr. Foley worked in business development at Genentech and in management consulting with Arthur D. Little. Mr. Foley currently serves as a member of the board of directors of Aires Pharmaceuticals, Inc., Celladon Corporation, Chiasma, Inc. and Selexys Pharmaceuticals Corporation. Mr. Foley received a B.S. in chemistry from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.

          Timothy Noyes

            Timothy P. Noyes
            President and Chief Executive Officer
            Timothy Noyes joined Proteon in 2006 as our President and Chief Executive Officer and has also been a member of our board of directors since joining the company. From 2002 to 2006, Mr. Noyes served as Chief Operating Officer of Trine Pharmaceuticals, Inc., a biopharmaceutical company. Before joining Trine, Mr. Noyes held several management positions with GelTex Pharmaceuticals from 1996 to 2001, prior to its acquisition by Genzyme Corporation. After the acquisition, from 2001 to 2002, he held the position of President, Renal Division and President, GelTex Pharmaceuticals. Prior to GelTex, he worked for several years at Merck & Co. across multiple roles in its hypertension and heart failure group and managed care division, and on its Vasotec and Prilosec products. Mr. Noyes received an A.B. from Harvard College and an M.B.A. from Harvard Business School.

            George Eldridge

              George A. Eldridge
              Senior Vice President and Chief Financial Officer
              George Eldridge joined Proteon in 2013 as our Chief Financial Officer. Prior to joining Proteon, from 2009 to 2013, Mr. Eldridge served as a consultant to companies in the biotechnology industry, acting as a chief financial officer and providing advisory services. From 2006 to 2009, Mr. Eldridge was Chief Financial Officer of Targanta Therapeutics Corporation until its acquisition by The Medicines Company. Before working at Targanta, Mr. Eldridge served as Chief Financial Officer of Therion Biologics from 2002 to 2006, and prior to that he served as Chief Financial Officer of Curis (previously Ontogeny) and Boston Life Sciences. Prior to working in the biotechnology field, Mr. Eldridge was an investment banker at Kidder Peabody & Co. He holds a B.A. from Dartmouth College and an M.B.A. from the University of Chicago.

              Steven Burke, M.D.

                Steven K. Burke, M.D.
                Senior Vice President and Chief Medical Officer
                Steven Burke, M.D., joined Proteon in 2006 as our Senior Vice President and Chief Medical Officer. Prior to joining Proteon, Dr. Burke served as Senior Vice President of Medical and Regulatory Affairs and Vice President of Clinical Research at Genzyme Corporation, where he worked from 2000 to 2006. From 1994 to 2000, Dr. Burke held roles at GelTex Pharmaceuticals, including Vice President of Clinical Research and Medical Director, and before that he held positions at Glaxo. Dr. Burke received an A.B. from Harvard College and an M.D. from Cornell University Medical College. He completed a medical residency and fellowship at Brigham and Women’s Hospital and is certified by the American Board of Internal Medicine.

                Timothy Noyes

                  Timothy P. Noyes
                  President and Chief Executive Officer
                  Timothy Noyes joined Proteon in 2006 as our President and Chief Executive Officer and has also been a member of our board of directors since joining the company. From 2002 to 2006, Mr. Noyes served as Chief Operating Officer of Trine Pharmaceuticals, Inc., a biopharmaceutical company. Before joining Trine, Mr. Noyes held several management positions with GelTex Pharmaceuticals from 1996 to 2001, prior to its acquisition by Genzyme Corporation. After the acquisition, from 2001 to 2002, he held the position of President, Renal Division and President, GelTex Pharmaceuticals. Prior to GelTex, he worked for several years at Merck & Co. across multiple roles in its hypertension and heart failure group and managed care division, and on its Vasotec and Prilosec products. Mr. Noyes received an A.B. from Harvard College and an M.B.A. from Harvard Business School.